Joel E. Gallant, MD, MPH
Professor of Medicine and Epidemiology
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Associate Director
Johns Hopkins AIDS Service
Baltimore, MD

Research Topics

• Antiretroviral therapy: phase 1 through 4 trials
  
  

Lecture and Writing Topics

• Antiretroviral therapy: strategies, drug resistance, toxicity
  
  

Current Professional Summary

Joel E. Gallant, MD, MPH, is Professor of Medicine in the Division of Infectious Diseases at the Johns Hopkins University School of Medicine in Baltimore and Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is the Associate Director of the Johns Hopkins AIDS Service. He is Director of the Garey Lambert Research Center, through which he has conducted dozens of clinical trials on the treatment of HIV infection. He is also an investigator in the HIV Prevention Trials Network (HPTN), the Acute Infection Early Disease Research Program (AIEDRP), the Multicenter AIDS Cohort Study (MACS), and the AIDS Clinical Trials Group (ACTG). Within the HPTN and ACTG, he has been involved in international clinical trials, especially in Chiang Mai, Thailand. Dr Gallant is co-author, with John G. Bartlett, of Medical Management of HIV Infection, which is updated annually. He is an Associate Editor of The Hopkins HIV Report, and is on the Editorial Board of the Johns Hopkins AIDS Service Web site, where he conducts interactive question and answer forums on HIV disease for patients and clinicians.


Committees and Organizations

• Member, Board of Directors, International AIDS Society–USA
• Fellow, American College of Physicians
• Fellow, Infectious Diseases Society of America
• Member, American Academy of HIV Medicine
• General Council, International AIDS Society
  
  

Honors and Awards

• John C. Hume Masters in Public Health Award
• Delta Omega Public Health Honor Society, Alpha Chapter
  
  

Education

• University of California Irvine School of Biological Sciences, BS (1979)
• University of California Irvine School of Social Ecology, BA (1980)
• University of California San Francisco, MD (1985)
• Yale-New Haven Hospital, Internal Medicine (1985-1988)
• The Johns Hopkins University School of Hygiene and Public Health, MPH (1990)
• The Johns Hopkins University of Medicine, Infectious Diseases (1990-1992)
  
  
  

Selected Publications

1. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120:932-944.
2. Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-225.
3. Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA. 2000;283:1329-1334.
4. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
5. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1541-1548.
6. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
7. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004;39:609-629.
8. Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-1948.
9. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS; ESS30009 Study. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192:1921-1930.
10. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-260.